Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  García Escudero, Ramón ^a   Martínez Cruz, Ana B ^a   Santos, Mirentxu ^a   Lorz, Corina ^a   Segrelles, Carmen ^a   Garaulet, Guillermo ^a   Saiz Ladera, Cristina ^a   Costa, Clotilde ^a   Buitrago Pérez, Águeda ^a   Dueñas, Marta ^a   Paramio, Jesús M ^a  

^a CIEMAT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; PROTEIN P53; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN CONJUGATING ENZYME E2C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; BREAST CANCER; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DISEASE ACTIVITY; EMBRYO; EMBRYONIC STEM CELL; EPIDERMIS; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROGNOSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SKIN CARCINOMA; SPECIES COMPARISON; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; ANIMAL; GENETICS; NEOPLASM; SKIN TUMOR;

MUS;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; MICE; NEOPLASMS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954464575     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-193     Document Type: Article

References (51)

1. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4:223-238. 10.1016/S1535-6108(03)00197-1, 14522256.
2. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005, 37:48-55.
3. Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, Nowak N, Albertson DG, Pinkel D, Collins C, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 2001, 29:459-464. 10.1038/ng771, 11694878.
4. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 447:966-971. 10.1038/nature05886, 2714968, 17515920.
5. O'Hagan RC, Chang S, Maser RS, Mohan R, Artandi SE, Chin L, DePinho RA. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2002, 2:149-155. 10.1016/S1535-6108(02)00094-6, 12204535.
6. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267. 10.1016/j.cell.2006.05.030, 16814713.
7. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009, 9:724-737. 10.1038/nrc2730, 19776742.
8. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137:413-431. 10.1016/j.cell.2009.04.037, 19410540.
9. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28:622-629. 10.1002/humu.20495, 17311302.
10. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
11. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006, 6:909-923. 10.1038/nrc2012, 17128209.
12. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009, 9:701-713.
13. Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009, 9:831-841.
14. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001, 29:418-425. 10.1038/ng747, 11694875.
15. Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, Moral M, Lorz C, Garcia-Escudero R, Paramio JM. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 2008, 68:683-692. 10.1158/0008-5472.CAN-07-3049, 18245467.
16. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428. 10.1038/nrc2131, 17508028.
17. Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, Berns A, Paramio JM, Vooijs M. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 2004, 131:2737-2748. 10.1242/dev.01148, 15148303.
18. Ruiz S, Santos M, Lara MF, Segrelles C, Ballestin C, Paramio JM. Unexpected roles for pRb in mouse skin carcinogenesis. Cancer Res 2005, 65:9678-9686. 10.1158/0008-5472.CAN-05-1853, 16266987.
19. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507. 10.1038/ng.127, 18443585.
20. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273. 10.1038/ng1180, 12808457.
21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
22. Eyfjord JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM, Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 1995, 55:646-651.
23. Martinez-Cruz AB, Santos M, Garcia-Escudero R, Moral M, Segrelles C, Lorz C, Saiz C, Buitrago-Perez A, Costa C, Paramio JM. Spontaneous tumor formation in Trp53-deficient epidermis mediated by chromosomal instability and inflammation. Anticancer Res 2009, 29:3035-3042.
24. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, Chinnaiyan AM. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007, 9:443-454. 10.1593/neo.07292, 1877973, 17534450.
25. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180. 10.1593/neo.07112, 1813932, 17356713.
26. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006, 66:10292-10301. 10.1158/0008-5472.CAN-05-4414, 17079448.
27. Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, Ares M, Haussler D. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA 2000, 97:262-267. 10.1073/pnas.97.1.262, 26651, 10618406.
28. Yeung KY, Bumgarner RE. Multiclass classification of microarray data with repeated measurements: application to cancer. Genome Biol 2003, 4:R83. 10.1186/gb-2003-4-12-r83, 329422, 14659020.
29. Theilhaber J, Connolly T, Roman-Roman S, Bushnell S, Jackson A, Call K, Garcia T, Baron R. Finding genes in the C2C12 osteogenic pathway by k-nearest-neighbor classification of expression data. Genome Res 2002, 12:165-176. 10.1101/gr.182601, 155256, 11779842.
30. Nguyen DV, Rocke DM. Multi-class cancer classification via partial least squares with gene expression profiles. Bioinformatics 2002, 18:1216-1226. 10.1093/bioinformatics/18.9.1216, 12217913.
31. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
32. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
33. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
34. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004, 101:9309-9314. 10.1073/pnas.0401994101, 438973, 15184677.
35. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006, 38:1043-1048. 10.1038/ng1861, 16921376.
36. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, Lozano G, Roop DR. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 2007, 117:1893-1901. 10.1172/JCI31721, 1904325, 17607363.
37. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008, 22:1337-1344. 10.1101/gad.1662908, 2377188, 18483220.
38. Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, vanOostrom CT, Beems RB, Hoogervorst EM, Schaap MM, Attardi LD, Jacks T, et al. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res 2007, 67:4648-4656. 10.1158/0008-5472.CAN-06-4681, 17510390.
39. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009, 69:3625-3633. 10.1158/0008-5472.CAN-08-3426, 19336573.
40. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
41. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
42. Chen R, Li L, Butte AJ. AILUN: reannotating gene expression data automatically. Nat Methods 2007, 4:879. 10.1038/nmeth1107-879, 2716375, 17971777.
43. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4:P3. 10.1186/gb-2003-4-5-p3, 12734009.
44. Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003, 4:R70. 10.1186/gb-2003-4-10-r70, 328459, 14519205.
45. Assou S, Le Carrour T, Tondeur S, Strom S, Gabelle A, Marty S, Nadal L, Pantesco V, Reme T, Hugnot JP, et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 2007, 25:961-973. 10.1634/stemcells.2006-0352, 1906587, 17204602.
46. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956. 10.1016/j.cell.2005.08.020, 16153702.
47. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006, 125:301-313. 10.1016/j.cell.2006.02.043, 16630818.
48. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. Genomic targets of the human c-Myc protein. Genes Dev 2003, 17:1115-1129. 10.1101/gad.1067003, 196049, 12695333.
49. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003, 100:8164-8169. 10.1073/pnas.1332764100, 166200, 12808131.
50. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028. 10.1182/blood-2005-11-013458, 1895543, 16728703.
51. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173. 10.1016/j.ccr.2006.02.019, 16530701.